---
title: "Adlai Nortye Announces First Patient Dosed in Intermittent Weekly Dosing Arm of Global Phase 1 Trial of Pan-RAS(ON) Inhibitor AN9025"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292896937.md"
description: "Adlai Nortye announced that the first patient has been dosed in the intermittent weekly arm of its global Phase 1 trial for AN9025, a pan-RAS(ON) inhibitor. This milestone advances the study's evaluation of the drug's efficacy and safety under this specific dosing regimen."
datetime: "2026-07-16T11:03:20.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292896937.md)
  - [en](https://longbridge.com/en/news/292896937.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292896937.md)
generator: "portal-rs"
---

# Adlai Nortye Announces First Patient Dosed in Intermittent Weekly Dosing Arm of Global Phase 1 Trial of Pan-RAS(ON) Inhibitor AN9025

The ongoing Phase 1 clinical trial of the pan-RAS(ON) inhibitor AN9025 has reached a milestone as the first patient has received a dose in the intermittent weekly dosing (QW) arm. This is a significant development in the study involving the potential treatment, with important implications for testing the drug's efficacy and safety. The trial aims to assess the impact of AN9025 on patients, with a focus on dosing regimen and outcomes. This progress marks a step forward in the evaluation of the inhibitor's effects, setting the stage for further advancements in the research.

### Related Stocks

- [ANL.US](https://longbridge.com/en/quote/ANL.US.md)

## Related News & Research

- [Adlai Nortye wins FDA IND clearance for AN4035 ADC trial expansion to US](https://longbridge.com/en/news/298307049.md)
- [Adlai Nortye: Buy Rating Reiterated as RAS-Targeted Pipeline Advances; $20 Price Target Maintained](https://longbridge.com/en/news/298344682.md)
- [These 2 ‘Monster Growth’ Stocks Aren’t Done Climbing, Say Analysts](https://longbridge.com/en/news/298130385.md)
- [Adlai Nortye (NASDAQ:ANL) Trading 7.7% Higher   - Still a Buy?](https://longbridge.com/en/news/298070798.md)
- [Major Insider Move Shakes Up Adlai Nortye’s Market Narrative](https://longbridge.com/en/news/297118427.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**